Bristol Myers Squibb Announces Phase III CheckMate -8HW Trial Evaluating Opdivo (Nivolumab) plus Yervoy (Ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary

Bristol Myers Squibb announced the Phase III CheckMate -8HW trial evaluating Opdivo plus Yervoy compared to investigator’s choice of chemotherapy as a first-line treatment for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer met the dual primary endpoint of progression-free survival.